title: Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR.
abstract: Progression of prostate cancer to androgen independence remains the primary obstacle to improved survival. The development of more effective treatments depends on our understanding of the molecular events associated with the hormone-refractory stage. We quantified, among 90 screened genes, the expression of 37 target genes, using real-time quantitative RT-PCR. Gene expression was studied in 13 samples of HPRC compared to 33 clinically localised cancers and normal prostate tissue. We identify 19 genes with significant differential expression in HRPC compared to localised prostate cancer. Genes with decreased expression included receptors for growth factors, MMR genes and the serine protease hepsin. Analysis of increased gene expression confirmed the importance of AR upregulation and highlighted genes not previously linked to HRPC, including enzymes involved in steroid synthesis and the antiapoptotic factor survivin. Progression of prostate cancer to the hormone-refractory state is associated with differential gene expression, which may prove useful for both understanding disease progression and the development of new therapeutic approaches.
authors.affiliation: Centre d' Etude et de Recherche en Pathologie Prostatique 3104, Université Paris VII, Paris, France. gaelle.fromont@imm.fr
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Fromont
authors.forename: Laurent
authors.initials: L
authors.lastname: Chene
authors.forename: Michel
authors.initials: M
authors.lastname: Vidaud
authors.forename: Guy
authors.initials: G
authors.lastname: Vallancien
authors.forename: Philippe
authors.initials: P
authors.lastname: Mangin
authors.forename: Georges
authors.initials: G
authors.lastname: Fournier
authors.forename: Pierre
authors.initials: P
authors.lastname: Validire
authors.forename: Alain
authors.initials: A
authors.lastname: Latil
authors.forename: Olivier
authors.initials: O
authors.lastname: Cussenot
mesh_terms: D000728:Androgens / Q000502:physiology* / Q000627:therapeutic use; D018076:DNA, Complementary; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D016147:Genes, Tumor Suppressor; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D011379:Prognosis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000235:genetics*; D012334:RNA, Neoplasm / Q000235:genetics / Q000302:isolation & purification; D011944:Receptors, Androgen / Q000235:genetics; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*; D015398:Signal Transduction
chemical_list: D000728:Androgens; D018076:DNA, Complementary; D012334:RNA, Neoplasm; D011944:Receptors, Androgen; D018160:Receptors, Cytoplasmic and Nuclear